4QL3
Crystal Structure of a GDP-bound G12R Oncogenic Mutant of Human GTPase KRas
4QL3 の概要
| エントリーDOI | 10.2210/pdb4ql3/pdb |
| 関連するPDBエントリー | 4LDJ 4OBE 4TQ9 4TQA 4WA7 |
| 分子名称 | GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (4 entities in total) |
| 機能のキーワード | small gtpase, signal transduction, gdp binding, gtp binding, hydrolase |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Cell membrane ; Lipid-anchor ; Cytoplasmic side : P01116 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 19896.46 |
| 構造登録者 | Hunter, J.C.,Manandhar, A.,Gurbani, D.,Chen, Z.,Westover, K.D. (登録日: 2014-06-10, 公開日: 2015-06-10, 最終更新日: 2024-02-28) |
| 主引用文献 | Hunter, J.C.,Manandhar, A.,Carrasco, M.A.,Gurbani, D.,Gondi, S.,Westover, K.D. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res., 13:1325-1335, 2015 Cited by PubMed Abstract: KRAS mutations are the most common genetic abnormalities in cancer, but the distribution of specific mutations across cancers and the differential responses of patients with specific KRAS mutations in therapeutic clinical trials suggest that different KRAS mutations have unique biochemical behaviors. To further explain these high-level clinical differences and to explore potential therapeutic strategies for specific KRAS isoforms, we characterized the most common KRAS mutants biochemically for substrate binding kinetics, intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activities, and interactions with the RAS effector, RAF kinase. Of note, KRAS G13D shows rapid nucleotide exchange kinetics compared with other mutants analyzed. This property can be explained by changes in the electrostatic charge distribution of the active site induced by the G13D mutation as shown by X-ray crystallography. High-resolution X-ray structures are also provided for the GDP-bound forms of KRAS G12V, G12R, and Q61L and reveal additional insight. Overall, the structural data and measurements, obtained herein, indicate that measurable biochemical properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF. PubMed: 26037647DOI: 10.1158/1541-7786.MCR-15-0203 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.041 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






